Reversal of immunoparalysis in humans in vivo: a double-blind, placebo-controlled, randomized pilot study. (Q54331733)

27 May 2018

title

Reversal of immunoparalysis in humans in vivo: a double-blind, placebo-controlled, randomized pilot study. (English)

1 reference

27 May 2018

1 reference

7

Mihai G Netea

1 reference

27 May 2018

Leo A.B. Joosten

5

object named as

Leo A B Joosten

1 reference

27 May 2018

Johannes G van der Hoeven

6

object named as

Johannes G van der Hoeven

1 reference

27 May 2018

author name string

Jenneke Leentjens

1

1 reference

27 May 2018

Matthijs Kox

2

1 reference

27 May 2018

Rebecca M Koch

3

1 reference

27 May 2018

Frank Preijers

4

1 reference

27 May 2018

Peter Pickkers

8

1 reference

27 May 2018

language of work or name

English

0 references

publication date

19 July 2012

1 reference

27 May 2018

American Journal of Respiratory and Critical Care Medicine

number of pages

8

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

27 May 2018

volume

186

1 reference

27 May 2018

page(s)

838-845

1 reference

27 May 2018

issue

9

1 reference

27 May 2018

Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201204-0645OC

Such stuff as dreams are made on: mediator-directed therapy in sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201204-0645OC

The late phase of sepsis is characterized by an increased microbiological burden and death rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201204-0645OC

Immunosuppression in patients who die of sepsis and multiple organ failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201204-0645OC

Immunotherapy for sepsis--a new approach against an ancient foe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201204-0645OC

Characterization and modulation of the immunosuppressive phase of sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201204-0645OC

The pathophysiology and treatment of sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201204-0645OC

Monocytic HLA-DR expression in intensive care patients: interest for prognosis and secondary infection prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201204-0645OC

The sepsis seesaw: tilting toward immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201204-0645OC

Diversity of interferon gamma and granulocyte-macrophage colony-stimulating factor in restoring immune dysfunction of dendritic cells and macrophages during polymicrobial sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201204-0645OC

A randomized phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201204-0645OC

Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201204-0645OC

Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201204-0645OC

Lipopolysaccharide-stimulated whole blood cytokine production does not predict the inflammatory response in human endotoxemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201204-0645OC

Differential ex vivo and in vivo endotoxin tolerance kinetics following human endotoxemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201204-0645OC

Development of endotoxin tolerance in humans in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201204-0645OC

The effect of systemic iNOS inhibition during human endotoxemia on the development of tolerance to different TLR-stimuli

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201204-0645OC

In vivo lipopolysaccharide exposure of human blood leukocytes induces cross-tolerance to multiple TLR ligands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201204-0645OC

Induction of IRAK-M is associated with lipopolysaccharide tolerance in a human endotoxemia model

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201204-0645OC

IFN-γ abrogates endotoxin tolerance by facilitating Toll-like receptor-induced chromatin remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201204-0645OC

Interferon gamma inhibits interleukin 10 production by monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201204-0645OC

IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201204-0645OC

Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201204-0645OC

Messenger RNA expression of major histocompatibility complex class II genes in whole blood from septic shock patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201204-0645OC

Monocyte human leukocyte antigen-DR transcriptional downregulation by cortisol during septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201204-0645OC

Monitoring temporary immunodepression by flow cytometric measurement of monocytic HLA-DR expression: a multicenter standardized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201204-0645OC

Predictive value of monocyte histocompatibility leukocyte antigen-DR expression and plasma interleukin-4 and -10 levels in critically ill patients with sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201204-0645OC

Changes of monocyte human leukocyte antigen-DR expression as a reliable predictor of mortality in severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201204-0645OC

A dynamic view of mHLA-DR expression in management of severe septic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201204-0645OC

Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, γ-interferon and interleukin-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201204-0645OC

10.1164/RCCM.201204-0645OC

21 January 2018

Identifiers

DOI

1 reference

27 May 2018

PubMed ID

22822024

1 reference

27 May 2018